



**Enlitic, Inc.**  
1635 Foxtrail Drive, Suite 111A  
Loveland, CO 80538

---

31 March 2026

## **Contract Secured with St. Jude Children’s Research Hospital**

- **St Jude is a globally recognised academic medical centre focused on advancing cures and improving outcomes for children with cancer and other life-threatening diseases**
- **Contract valued at US\$250,000 for the provision of data migration services**
- **Provides a catalyst for the potential adoption of ENL’s AI-powered data management platform, Ensign, which, if adopted, would deliver higher-margin SaaS revenue beyond migration**
- **First commercial engagement in the paediatric healthcare sector, expanding addressable market into a high-value segment and providing strong third-party validation**
- **Takes the value of new contracts secured in March to US\$1.75m alone following US\$1.5m contract with Penn Medicine awarded earlier this month**
- **Contract demonstrates Enlitic’s strengthening sales and partnership pipeline, both directly with leading healthcare facilities and institutions and through leading global OEMs where the Company has multiple commercial engagements**

Enlitic, Inc. (ASX: ENL) is pleased to advise it has entered into a new collaboration agreement with St. Jude Children’s Research Hospital (“St. Jude”), a globally recognised not-for-profit paediatric care institution in Memphis, Tennessee for the deployment of its core data migration technology.

St. Jude is a world leading academic medical centre focused on advancing cures and improving outcomes for children with cancer and other life-threatening diseases. The institution combines high-volume clinical care with world-leading research programs and large-scale data-driven initiatives, positioning it at the forefront of paediatric oncology and precision medicine. Importantly, St. Jude operates one of the most advanced paediatric research and clinical data ecosystems globally, with a strong emphasis on the integration and utilisation of imaging and genomic datasets to drive discovery and treatment innovation.

Under the terms of the agreement, Enlitic will provide migration services to St. Jude valued at US\$250,000. Significantly, the migration services contract provides the catalyst for St. Jude to potentially access Enlitic’s AI-powered data management platform, Ensign, which delivers a cohort of higher-margin SaaS-based offerings on top of the Company’s core data migration initiatives.

The Ensign platform is an enterprise SaaS imaging solution that enables healthcare providers to efficiently access, manage and utilise large-scale medical imaging datasets, supporting streamlined workflows, improved interoperability and the deployment of advanced analytics and AI-driven applications.

The arrangements with St Jude represent Enlitic's first commercial engagement within the paediatric healthcare sector, providing a strategic entry point into a highly specialised and research-intensive segment of the global healthcare market. Establishing a relationship with an institution of St. Jude's calibre provides strong third-party validation of Enlitic's platform and creates potential to expand into adjacent paediatric and research-led health systems, supporting long-term growth in both clinical and research data management applications.

**Enlitic CEO Michael Sistenich said:** *"This strategic relationship is another strong validation of our technology and reflects the growing need among healthcare providers for solutions that extend beyond migration and standardisation, supporting a more effective approach to managing their data over time. We are proud to work with such a respected healthcare institution as St. Jude on an engagement which supports those priorities.*

*"It is also encouraging to note that our data migration technology continues to gain traction through OEM channels and directly with leading healthcare institutions in North America. The growing number of migration contracts provides us with multiple channels to roll out and integrate our AI-driven Insight offering which has exceptional functionality and considerable commercial appeal to customers."*

**ENDS**

This announcement was authorised for release by the Board of Enlitic, Inc.

## **Enquiries**

### **Enlitic Investor Relations**

Australia:

invest\_au@enlitic.com

## **About Enlitic**

Enlitic is a software company that uses artificial intelligence to develop software products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray and ultrasound images) and licences such products to healthcare providers. Enlitic's products (including its current product offering and product suite under development) seek to standardise, protect, integrate, and analyse data to create the foundation of a real-world evidence platform that can improve clinical workflows, increase efficiencies, and expand capacity. Read more at [enlitic.com](http://enlitic.com).

Enlitic's CDIs are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933 as amended, and in accordance with the procedures established pursuant to the provisions of a no action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this announcement.